Barclays Maintains Overweight Rating on Iron Mountain (IRM), Lifts PT
On May 27, Barclays raised its price target on Iron Mountain Incorporated (NYSE:IRM) to $121 from $118 and maintained an Overweight rating.
The rating update came with the firm's update of models in the data center group and the company's fiscal Q1 2025 earnings, which showed record performance in revenue and adjusted EBITDA.
A storage facility with boxes and shelves to store records, representing the company's secure records storage.
Iron Mountain Incorporated (NYSE:IRM) reported record fiscal Q1 2025 revenue of $1.6 billion, reflecting a 7.8% growth on a reported basis and 9.4% growth excluding the effects of foreign exchange. The improved results were attributed to strong performance across the company's business, with its growth businesses of data center, digital, and asset lifecycle management (ALM) collectively rising more than 20%.
The company also delivered a record first-quarter adjusted EBITDA of $580 million and increased its 2025 guidance based on these results. On May 1, Iron Mountain Incorporated (NYSE:IRM) declared a quarterly cash dividend of $0.785 per share for Q2 2025.
Iron Mountain Incorporated (NYSE:IRM) provides storage and information management solutions. Its operations are divided into the following business segments: Global Records & Information Management Business, Global Data Center Business, and Corporate & Other Business.
While we acknowledge the potential of IRM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than IRM and that has 100x upside potential, check out our report about the .
READ NEXT: and .
Disclosure: None.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
35 minutes ago
- Forbes
FDA's New AI Tool Cuts Review Time From 3 Days To 6 Minutes
AI at the FDA getty The U.S. Food and Drug Administration announced this week that it deployed a generative AI tool called ELSA (Evidence-based Learning System Assistant), across its organization. After a low-profile pilot that delivered measurable gains, the system is now in use by staff across the agency, several weeks ahead of its original schedule. Dr. Marty Makary, the FDA's commissioner, shared a major outcome. A review task that once took two or three days now takes six minutes. 'Today, we met our goal ahead of schedule and under budget,' said Makary. 'What took one scientific reviewer two to three days [before] The FDA has thousands of reviewers, analysts, and inspectors who deal with massive volumes of unstructured data such as clinical trial documents, safety reports, inspection records. Automating any meaningful portion of that stack creates outsized returns. ELSA helps FDA teams speed up several essential tasks. Staff are already using it to summarize adverse event data for safety assessments, compare drug labels, generate basic code for nonclinical database setup, and identify priority sites for inspections, among other tasks. This last item, using data to rank where inspectors should go, could have a real-world impact on how the FDA oversees the drug and food supply chain and impacts on how the FDA delivers its services. Importantly, however, the tool isn't making autonomous decisions without a human in the loop. The system prepares information so that experts can decide faster. It cuts through the routine, not the judgment. One of the biggest questions about AI systems in the public sector revolves around the use of data and third party AI systems. Makary addressed this directly by saying that 'All information stays within the agency. The AI models are not being trained on data submitted by the industry.' That's a sharp contrast to the AI approaches being taken in the private sector, where many large language models have faced criticism over training on proprietary or user-submitted content. In the enterprise world, this has created mounting demand for "air-gapped" AI solutions that keep data locked inside the company. That makes the FDA's model different from many corporate tools, which often rely on open or external data sources. The agency isn't building a public-facing product. It's building a controlled internal system, one that helps it do its job better. Federal departments have been slow to move past AI experimentation. The Department of Veterans Affairs has started testing predictive tools to manage appointments. The SEC has explored market surveillance AI for years. But few have pushed into full and widespread production. The federal government has thousands of employees processing huge volumes of information, most of it unstructured sitting in documents, files, and even paper. That means AI is being focused most on operational and process-oriented activities. It's shaping up to be a key piece of how agencies process data, make recommendations, and act. Makary put it simply that ELSA is just the beginning for AI adoption within the FDA. 'Today's rollout of ELSA will be the first of many initiatives to come,' he said. 'This is how we'll better serve the American people.'
Yahoo
38 minutes ago
- Yahoo
Procter & Gamble plans to slash 7,000 non-manufacturing jobs over next 2 years
-- Procter & Gamble (NYSE:PG) plans to cut around 7,000 jobs, or roughly 15% of its global non-manufacturing workforce, over the next two years. The move is part of a broader organizational overhaul aimed at simplifying structures by forming smaller teams with expanded responsibilities. The company emphasized that the layoffs are not a cost-cutting measure. The consumer goods maker, known for brands like Tide, Pampers and Bounty, had about 108,000 employees as of last June. Executives announced the restructuring plans during a presentation in Paris, where they also signaled an intention to streamline the company's product portfolio. While specific details were not provided, the changes could involve exiting certain categories and shedding smaller brands in select markets. In April, P&G reported a decline in quarterly sales and lowered its full-year revenue outlook, citing global economic uncertainty and geopolitical instability. The company posted earnings per share (EPS) of $1.54 for the third quarter of fiscal 2025, slightly above the $1.53 that analysts expected. Revenue came in at $19.78 billion, falling short of the $20.11 billion forecast. It also said it was exploring ways to manage the impact of tariffs, including raising prices, reformulating products and tightening costs. Chief Financial Officer Andre Schulten said current tariffs are expected to reduce annual growth by $1 billion to $1.5 billion. To offset the impact, the company plans to rely on pricing, productivity, and innovation in the near term, while also exploring changes in product formulation and sourcing. With one quarter remaining in its fiscal year, P&G currently anticipates flat sales growth for fiscal 2025, a downgrade from its previous projection of 2% to 4%. It also lowered its core earnings outlook to a range of $6.72 to $6.82 per share, down from the earlier forecast of $6.91 to $7.05. Related articles Procter & Gamble plans to slash 7,000 non-manufacturing jobs over next 2 years Citigroup to cut 3,500 jobs at China tech centers BofA sees 62% surge in eVTOL adoption, fueling 'low-altitude' boom Sign in to access your portfolio
Yahoo
39 minutes ago
- Yahoo
Jim Cramer Says to 'Buy Dover (DOV) Right Now'
We recently published a list of . In this article, we are going to take a look at where Dover Corporation (NYSE:DOV) stands against other stocks that Jim Cramer discusses. Inquiring about Dover Corporation (NYSE:DOV), a caller asked if Cramer thinks that the stock will ever hit $222. He replied: 'I look wrong right now on Dover for the club… but I think I'm going to be right. Why? Because I think that Tobin is very smart, the CEO and the stock should never have been thrown back, 19 times earnings. It even went down when steel tariffs went on. I say enough is enough. Buy Dover right now, tomorrow morning.' A modern industrial equipment assembly line in motion. Dover (NYSE:DOV) produces items like pumps, flow meters, refrigeration systems, printing and coding equipment, vehicle lifts, winches, and fluid dispensing tools. Additionally, the company provides software and services used in fuel handling, industrial processing, climate control, and product traceability across various industries. During an episode of Squawk on the Street in April, Cramer commented: 'Okay so here's a good example of the craziness of this market. Dover reports. Dover did what RTX did the other day. They actually said okay listen the tariffs are hurting us. Okay, here's how they're hurting us. Stock was immediately down seven bucks. Down 7. And I was like I own it for my charitable trust and I'm like meumughmhgm . . .and then well people figured out, wait a second, they told the truth! Now the stock's up nice.' READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
